On February 8th, 2020, National Health Commission of the People\'s Republic of China issued the *Diagnosis and Treatment Plan of Corona Virus Disease 2019 (Tentative Fifth Revised Edition)*.

Since December 2019, Wuhan City, Hubei Province has successively discovered multiple cases of patients with Corona Virus Disease 2019 (COVID-19). With the spread of the epidemic, other cases in China and abroad have also been found. Most of the currently reported cases have a history of residence or travel in Wuhan, but cases without that have already been found in some areas. As an acute respiratory infectious disease, COVID-19 has been classified into the Class B communicable diseases stipulated by *the Law on the Prevention and Treatment of Infectious Diseases of the People\'s Republic of China*, and managed as a Class A communicable diseases.

After the outbreak, National Health Commission of the People\'s Republic of China organized relevant experts to formulate the tentative first edition, second edition, third edition, fourth edition and fifth edition of *Diagnosis and Treatment Plan of Corona Virus Disease 2019*.

The tentative fifth revised edition includes the characteristics of coronavirus pathogens, clinical characteristics, case definitions, differential diagnosis, case identify and report, treatment, release of isolation and discharge standards, transfer principles, and nosocomial infection control.

1. Characteristics of coronavirus pathogens {#s0005}
===========================================

The coronavirus subfamilies are categorized into four genera: α, β, γ, and δ. Coupled with this newly discovered coronavirus, seven types of coronaviruses are known to infect humans. Most coronaviruses cause upper respiratory tract infections, but Middle East respiratory syndrome coronavirus (MERSr-CoV), severe acute respiratory syndrome associated coronavirus (SARSr-CoV) and the novel coronavirus 2019 (2019-nCoV, officially named as severe acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\] by International Committee on Taxonomy of Viruses) can cause mild and even severe pneumonia, and can be transmitted from person to person.

Coronaviruses are sensitive to ultraviolet rays and heat, and can be effectively inactivated by a majority of disinfectants except chlorhexidine. Therefore, hand sanitizers containing chlorhexidine are not recommended for use here.

2. Epidemiological characteristics {#s0010}
==================================

The source of infection is changed to "The major source of infection currently is the patients with COVID-19, and asymptomatic 2019-nCoV carriers can also be the source of infection".

3. Clinical characteristics {#s0015}
===========================

The incubation period of COVID-19 is 1 to 14 days, and generally within 3 to 7 days. Fever, fatigue and dry cough are considered the main manifestations along with symptoms such as stuffy nose, runny nose, and diarrhea in a few patients. Because some severe patients have no obvious dyspnea and present with hypoxemia, the text is changed to "In severe cases, dyspnea and/or hypoxemia usually occurs after a week of disease onset, and the worse can rapidly progress to acute respiratory distress syndrome, septic shock, metabolic acidosis that is hard to balance, and hemorrhage and coagulation dysfunction, etc.". This edition highlights that "Mild patients only present with low fever, mild fatigue and so on, but without manifestation of pneumonia".

In terms of laboratory examination, this edition adds the following descriptions, "Increased values of liver enzymes, lactate dehydrogenase, muscle enzymes and myoglobin can occur in some patients; and raised level of troponin can be seen in some critical patients" and "The nucleic acid of 2019-nCoV can be detected in biological specimens such as nasopharyngeal swabs, sputum, secretions of lower respiratory tract, blood and feces".

In the early stage of COVID-19, the images show that there are multiple small patches shadows and interstitial changes, especially in the lung periphery. As the disease progresses, the images of these patients further develop into multiple ground glass shadows and infiltration shadows in both lungs. In severe cases, lung consolidation may occur. It is seldom to find pleural effusion in patients with COVID-19.

4. Case diagnosis {#s0020}
=================

It is different between Hubei Province and other provinces.

Cases in other provinces except Hubei are still classified into "suspected cases" and "confirmed cases". Based on the fact that confirmed cases with no definite epidemiological exposure history have been found, "Those without definite epidemiological exposure history but meeting the three clinical manifestations (fever and/or respiratory symptoms; having the imaging features of pneumonia mentioned above; in the early stage, a normal or decrease of total white blood cells count and a decrease of lymphocyte count can be found)" are also included in the investigation of suspected cases. The diagnostic criteria for confirmed cases remain unchanged. (A positive result of the nucleic acid of 2019-nCoV by real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR) in respiratory tract specimens or blood specimens, or the virus gene sequence of respiratory tract specimens or blood specimens is highly homologous to the known 2019-nCoV.)

A classification of "clinical diagnosis cases" was added in Hubei Province. Moreover, the standard of "suspected cases" is revised to, "Patients regardless of whether with an epidemiological history can be considered suspected cases as long as they satisfy the two clinical manifestations: 'fever and/or respiratory symptoms' and 'in the early stage, a normal or decrease of total white blood cells count and a decrease of lymphocyte count can be found'". It means that the diagnostic criteria of suspected cases have been relaxed. Suspected cases with imaging features of pneumonia are clinically diagnosed cases. The diagnostic criteria for confirmed cases remain unchanged.

5. Clinical classifications {#s0025}
===========================

According to whether with clinical symptoms or pneumonia, the severity of pneumonia, whether with respiratory failure or shock, and whether with other organs failure, cases are divided into mild cases (clinical symptoms are mild, and no pneumonia can be found in imaging); ordinary cases (with symptoms like fever and respiratory tract, etc. and pneumonia manifestation can be seen in imaging); severe cases (respiratory distress, respiratory rate (RR) ≥30 breaths/min; pulse oxygen saturation (SpO~2~) ≤93% on room air at rest state; arterial partial pressure of oxygen (PaO~2~)/oxygen concentration (FiO~2~) ≤300mmHg); and critical cases (respiratory failure occurs and mechanical ventilation is required; shock occurs; complicated with other organ failure that requires monitoring and treatment in ICU).

6. Differential diagnosis {#s0030}
=========================

There are more than 100 species of pathogens that cause community-acquired pneumonia, of which viruses account for about 30%, and others viruses which cause pneumonia have something in common with the common influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARSr-CoV, etc. It is difficult to distinguish from clinical manifestations and chest imaging alone, while pathogenic testing is needed.

7. Case identification, report and exclusion {#s0035}
============================================

Hubei Province is different from other provinces.

In provinces other than Hubei, the case identification and reporting procedures are the same as the fourth edition of the *Diagnosis and Treatment Plan*, but the present edition emphasizes the safety of transfer and transfer the suspected patient to the designated hospital as soon as possible.

For Hubei Province, medical staff at all levels and types of medical institutions are required to immediately isolate and treat suspected and clinically diagnosed cases that meet the definition of the case. Every suspected or clinically diagnosed case should be isolated in a single room. And the specimens should be collected for pathogenic testing as soon as possible.

Suspected cases can be excluded after the nucleic acid test for respiratory pathogens is negative for two consecutive times (sampling interval at least 1 day).

8. Treatment {#s0040}
============

The treatments include isolation, symptomatic support, and close monitoring of condition changes, especially breathing rate and finger pulse oxygen saturation.

Every suspected case should be treated in single room, while confirmed cases can be admitted to the same ward.

Critical cases should be admitted to the ICU as soon as possible.

Antibiotics use: Blind or inappropriate use of antibiotics should be avoided, especially in combination with broad-spectrum antibiotics.

Antiviral treatment: This edition adds the description of "no effective antiviral treatment is currently confirmed". Based on trying drugs of alpha-interferon aerosol inhalation and lopinavir/ritonavir, "or add ribavirin" is supplemented. After full discussion by the National COVID-19 Medical Treatment Expert Group, the dosage of ribavirin has been adjusted to 500mg each time for adults with 2 to 3 times of intravenous infusions per day, considering the safety of its high-dose. At the same time, pay attention to lopinavir/ritonavir associated side effects, such as diarrhea, nausea, vomiting, liver damage, and the interactions with other drugs.

The key to reduce case fatality rate is successful treatment of severe and critical cases. Prevent and cure complications actively, treat basic diseases, prevent secondary infections, and provide timely organ function supports. Patients always feel anxious and frightened, psychological counseling should be strengthened.

On monitoring of disease, "cytokine detection is feasible for those people who have condition" has been supplemented.

Respiratory support: (1) Oxygen therapy: Severe patients should be provided inhalation oxygen with facemask or nasal catheter, and timely assess whether respiratory distress and/or hypoxemia are relieved. (2) High-flow nasal catheter oxygen therapy or non-invasive mechanical ventilation: when respiratory distress and/or hypoxemia can not be relieved after standard oxygen therapy, high-flow nasal catheter oxygen therapy or non-invasive ventilation should be considered. It is highlighted that "if the condition does not improve or even worsen within a short time (1--2 hours), endotracheal intubation and invasive mechanical ventilation should be performed promptly". (3) Invasive mechanical ventilation: lung protective ventilation strategies should be used, which means small tidal volume (4--8ml/kg ideal weight) and low inspiratory pressure (platform pressure \<30 cmH~2~O) for mechanical ventilation to reduce ventilator-related lungs injuries. (4) For patients with severe acute respiratory distress syndrome (ARDS), it is recommended to perform lung expansion. If possible, prone position ventilation should be performed for more than 12 hours per day. For those with poor prone position ventilation, extracorporeal membrane oxygenation (ECMO) should be considered as soon as possible if conditions permit.

Circulation support: On the basis of adequate fluid resuscitation, improve microcirculation, use vasoactive drugs, and perform hemodynamic monitoring when necessary.

Other treatment measures: Glucocorticoids can be used in a short period of time (3--5 days) according to the severity of respiratory distress and the progress of chest imaging. The recommended dose of methylprednisolone should not exceed 1--2mg/(kg∙day). It should be noted that higher doses of glucocorticoids would delay coronavirus clearance due to immunosuppressive effects. Xuebijing injection (a traditional Chinese medicine) can be given intravenously 100 ml/day, twice a day for treatment. Microecological preparation can be used to keep the equilibrium for intestinal microecology and prevent secondary bacterial infection. Convalescent plasma therapy can be used. For critically ill patients with high inflammatory response, extracorporeal blood purification technology can be considered when conditions permit.

Chinese medicine treatment measures: COVID-19 belongs to the category of traditional Chinese medicine epidemic disease. It is caused by the epidemic pathogenic factors, and is located in the lung. The basic pathogenesis of COVID-19 is characterized by dampness, heat, poison, and silt. Different regions can refer to the following schemes for dialectical treatment according to the disease condition, local climate characteristics, and different physical conditions.

9. Release of isolation and discharge standards {#s0045}
===============================================

Based on "with normal body temperature for more than 3 days, and significantly recovered respiratory symptoms", that *"*with obvious features of absorption of inflammation shown in lung imaging*"* has been added. In addition, patients should also meet the criterion of negative results of the nucleic acid tests of respiratory pathogens for consecutive two times (sampling interval at least 1 day). Only all the above criteria satisfying can the patients be released from the hospital or transferred to the corresponding departments for other diseases according to their conditions.

10. Transfer principle {#s0050}
======================

In order to ensure the safety of transport, patients should be transported in special vehicles, personal protection of transport personnel and vehicle disinfection should be done.
